Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Aeterna Jumps on FDA Fast-Track Status Request: Montreal Mover

July 24 (Bloomberg) -- Aeterna Zentaris Inc. rose the most in almost three weeks after the biotech company said it would ask the U.S. Food and Drug Administration to fast-track the approval process for its proposed test to diagnose growth hormone deficiency.

Aeterna, based in Quebec City, jumped 7 percent to 46 Canadian cents by 4 p.m. in Toronto, its largest single-day gain since July 5.

The FDA is due to respond to the request within 60 days, Aeterna said today in a statement. Aeterna expects to complete its submission for the AEZS-130 diagnostic test in the first quarter of 2013 if the FDA grants fast-track status, the company said.

To contact the reporter on this story: Frederic Tomesco in Montreal at tomesco@bloomberg.net

To contact the editor responsible for this story: Ed Dufner at edufner@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.